Quell (fibromyalgia treatment device)

2022: Announcement

On November 3, 2022, NeuroMetrix announced the launch of its Quell chronic musculoskeletal pain (fibromyalgia) treatment device. The project was implemented as part of the Pathfinder program.

Quell's device uses nerve stimulation to treat chronic pain, sending signals to the brain that cause it to release natural opioids. The developers plan a full commercial launch of Quell in the second quarter of 2023.

Quell

Fibromyalgia is a chronic disease that is manifested by pain, stiffness and soreness of muscles, tendons, and joints. The disease is characterized by sleep disturbance, feeling chronic fatigue, depression, anxiety, impaired bowel function. In typical cases, the attack lasts from 4 to 72 hours, while the symptoms can be pronounced. Fibromyalgia is a fairly common disease, sometimes referred to as fibrositis or myofascial pain syndrome

{{quote 'We're excited to start the Pathfinder Program! Partnering with these physicians, some of the most advanced clinicians at the forefront of fibromyalgia control, we will refine our messaging and distribution process to increase market access and ultimately give patients the best chance of our technology success, said NeuroMetrix CEO Dr. Shai Gozani. }} The Pathfinder Program starts on December 1, 2022, and is limited to 25 key physicians in key positions in fibromyalgia practice throughout the territory. USA The recommendations of key physicians are designed to help NeuroMetrix communicate information the benefits of Quell to patients and professionals. health care^[1]

Notes